Key facts
- This page summarizes Michel Detheux's Form 4 filing for Vor Biopharma Inc. (VOR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2026, 20:42.
Michel Detheux - 11 Jun 2026 Form 4 Insider Report for Vor Biopharma Inc. (VOR)
- Reporting relationship
- Director
- Issuer ticker
- VOR
- Reported as of
- 11 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2026, 20:42:40 UTC
- Prior SEC filing
- 29 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adi Osovsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michel Detheux filed Form 4 for Vor Biopharma Inc. (VOR) on 12 Jun 2026.
Change
- Previous filing in this sequence was filed on 29 Aug 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001816196
Primary reporting owner
Detheux Michel
- Relationship
- Director
- Address
- 500 BOYLSTON STREET, SUITE 1350, BOSTON
- Signature
- /s/ Adi Osovsky, Attorney-in-Fact
- Signature date
- 12 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VOR
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +57,162
- Change %
- Price
- $0.000000*
- Shares after
- 57,162
- Date
- 11 Jun 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 57,162
- Exercise price
- $14.09
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.